

41443



1635  
PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Michael EISENHUT et al

Serial No.: 09/781,980

Filed: 14 February 2001

For: OLIGONUCLEOTIDE CONJUGATES

Group Art Unit: 1635

Examiner: J. Schultz

#9/K.T.  
2/26  
A

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
FEB 19 2003  
TECH CENTER 1600/2900

Sir:

This Amendment is in response to the Office Action mailed 13 August 2002.

Attached hereto and herein incorporated by reference is a Petition for Extension of Time for a three-month extension making the due date for response 13 February 2003.

Kindly amend the application as follows.

IN THE SPECIFICATION:

Kindly substitute the last paragraph on page 10 with the following:

A'  
The inhibition of bcl-2 is preferred, since a large number of tumor types show an aberrant expression of the proto-oncogene bcl-2, which results in an increase of the concentration of the protein bcl-2. As is known, this protein inhibits apoptosis. Thus, the inhibition of the expression of the bcl-2 gene so as to effect apoptosis of the tumor cells and thus the elimination of the tumor, is a significant approach for a cancer therapy. Therefore,